CYP1B1 Promotes PARPi-Resistance via Histone H1.4 Interaction and Increased Chromatin Accessibility in Ovarian Cancer

Ovarian cancer is the most lethal gynecological cancer and presents significant therapeutic challenges. The discovery of synthetic lethality between PARP inhibitors (PARPi) and homologous recombination deficiency marked a new era in treating BRCA1/2-mutated tumors. However, PARPi resistance remains a major clinical challenge.